Gilead Sciences (GILD) Stock Forecast & Price Target

$114.55 -3.31 (-2.81%)

Closing price 09/12/2025 04:00 PM Eastern

Extended Trading

$115.96 +1.41 (+1.23%)

As of 09/12/2025 07:57 PM Eastern

Compare

Gilead Sciences - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Moderate Buy

Based on 27 Analyst Ratings

Sell
0

Hold
6

Buy
21

Based on 27 Wall Street analysts who have issued ratings for Gilead Sciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 27 analysts, 6 have given a hold rating, 18 have given a buy rating, and 3 have given a strong buy rating for GILD.

Consensus Price Target

$115.39
0.73% Upside

According to the 27 analysts' twelve-month price targets for Gilead Sciences, the average price target is $115.39. The highest price target for GILD is $140.00, while the lowest price target for GILD is $95.00. The average price target represents a forecasted upside of 0.73% from the current price of $114.55.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for GILD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Gilead Sciences and its competitors.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GILD Analyst Ratings Over Time

Type	Current Forecast 9/13/24 to 9/13/25	1 Month Ago 8/14/24 to 8/14/25	3 Months Ago 6/15/24 to 6/15/25	1 Year Ago 9/14/23 to 9/13/24
Strong Buy	3 Strong Buy rating(s)	2 Strong Buy rating(s)	3 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	18 Buy rating(s)	16 Buy rating(s)	15 Buy rating(s)	7 Buy rating(s)
Hold	6 Hold rating(s)	7 Hold rating(s)	9 Hold rating(s)	12 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$115.39	$114.82	$110.55	$82.06
Forecasted Upside	0.73% Upside	-3.53% Downside	0.51% Upside	-0.91% Downside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

GILD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GILD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Gilead Sciences Stock vs. The Competition

Type	Gilead Sciences	Medical Companies	S&P 500
Consensus Rating Score	2.89	2.78	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	0.73% Upside	17,449.70% Upside	10.73% Upside
News Sentiment Rating	Positive News See Recent GILD News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/5/2025	Dbs Bank 0 of 5 stars		Upgrade	Moderate Buy
8/19/2025	Daiwa America 5 of 5 stars		Upgrade	Hold ➝ Strong-Buy
8/19/2025	Daiwa Capital Markets 2 of 5 stars		Upgrade	Neutral ➝ Outperform	$128.00	+8.48%
8/8/2025	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Abrahams Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Sector Perform	$96.00 ➝ $98.00	-17.79%
8/8/2025	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Colin Bristow Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$108.00 ➝ $112.00	-6.78%
8/8/2025	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Asthika Goonewardene Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$108.00 ➝ $127.00	+15.16%
7/25/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Stringer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$133.00	+17.49%
4/25/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Harrison Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$130.00 ➝ $135.00	+30.24%
4/25/2025	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Hartaj Singh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$132.00 ➝ $125.00	+20.59%
4/22/2025	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Carter Gould Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Overweight	$125.00	+19.81%
Get the Latest News and Ratings for GILD and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Gilead Sciences and its competitors with MarketBeat's FREE daily newsletter.
3/27/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Chris Schott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$120.00 ➝ $130.00	+17.10%
3/5/2025	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tim Anderson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$116.00 ➝ $126.00	+9.00%
3/5/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	M. Bansal Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$120.00 ➝ $140.00	+21.20%
2/18/2025	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	James Shin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$80.00 ➝ $120.00	+15.30%
2/13/2025	DZ Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Buy	$108.00	+4.54%
2/12/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Salveen Richter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$85.00 ➝ $96.00	-7.27%
2/12/2025	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Evan Seigerman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$110.00 ➝ $115.00	+10.74%
2/12/2025	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Catanzaro Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$105.00 ➝ $110.00	+6.33%
11/21/2024	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Outperform	$90.00 ➝ $100.00	+12.83%
11/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	A. Hammond Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform	$110.00	+19.42%
11/14/2024	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Buy	$125.00	+34.95%
11/8/2024	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	M. Okunewitch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Hold
11/7/2024	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Neutral	$80.00 ➝ $95.00	-2.30%
11/7/2024	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Equal Weight	$84.00 ➝ $95.00	-1.72%
10/21/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	D. Graybosch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
10/21/2024	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$74.00 ➝ $96.00	+10.70%
10/17/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	C. Breen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform	$105.00	+21.04%
8/9/2024	Evercore ISI Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	U. Raffat Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong-Buy
7/8/2024	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$93.00	+39.45%
4/26/2024	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$90.00 ➝ $85.00	+29.99%
4/24/2024	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Reduce ➝ Hold	$69.00	+2.99%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 03:35 AM ET.

Should I Buy Gilead Sciences Stock? GILD Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, September 11, 2025. Please send any questions or comments about these Gilead Sciences pros and cons to contact@marketbeat.com.

Gilead Sciences
Bull Case

Here are some ways that investors could benefit from investing in Gilead Sciences, Inc.:

The current stock price is around $115.25, which may present a buying opportunity for investors looking for growth in the biopharmaceutical sector.
Recent upgrades from multiple analysts, including a "buy" rating from Truist Financial and a target price increase to $127.00, indicate positive market sentiment and potential for stock appreciation.
Gilead Sciences, Inc. has a strong market capitalization of approximately $143 billion, suggesting stability and a solid foundation for future growth.
Insider trading activity shows confidence in the company, with significant shares sold by executives, which can indicate a strategic repositioning rather than a lack of confidence.
The company has a favorable price-to-earnings (P/E) ratio of 22.96, which can be attractive compared to industry averages, suggesting that the stock may be undervalued relative to its earnings potential.

Gilead Sciences
Bear Case

Investors should be bearish about investing in Gilead Sciences, Inc. for these reasons:

Insiders have sold a significant number of shares recently, totaling 82,000 shares valued at over $9 million, which could raise concerns about the company's future performance.
The company has experienced a slight decline in stock value, down about 0.4%, which may indicate market volatility or investor uncertainty.
Despite recent upgrades, the consensus rating remains a "Moderate Buy," suggesting that not all analysts are fully confident in the stock's immediate prospects.
Gilead Sciences, Inc. has a debt-to-equity ratio of 1.13, indicating that the company has a relatively high level of debt compared to its equity, which could pose risks in a rising interest rate environment.
Recent insider sales and a low percentage of insider ownership (0.27%) may suggest a lack of alignment between management and shareholder interests, which can be a red flag for potential investors.

GILD Forecast - Frequently Asked Questions

: According to the research reports of 27 Wall Street equities research analysts, the average twelve-month stock price forecast for Gilead Sciences is $115.39, with a high forecast of $140.00 and a low forecast of $95.00.
: 27 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 6 hold ratings, 18 buy ratings and 3 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GILD shares.
: According to analysts, Gilead Sciences's stock has a predicted upside of 0.73% based on their 12-month stock forecasts.
: Over the previous 90 days, Gilead Sciences's stock had 5 upgrades by analysts.
: Gilead Sciences has been rated by research analysts at Daiwa America, Daiwa Capital Markets, Dbs Bank, Needham & Company LLC, Royal Bank Of Canada, Truist Financial, and UBS Group in the past 90 days.
: Analysts like Gilead Sciences more than other "medical" companies. The consensus rating score for Gilead Sciences is 2.89 while the average consensus rating score for "medical" companies is 2.78. Learn more on how GILD compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:GILD) was last updated on 9/13/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gilead Sciences (GILD) Stock Forecast & Price Target